View : 70 Download: 0

Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs

Title
Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs
Authors
Masaki T.Leypoldt J.K.Kamerath C.D.Mohammad S.F.Cheung A.K.Kim S.-J.
Ewha Authors
김승정
SCOPUS Author ID
김승정scopus
Issue Date
2004
Journal Title
Journal of Laboratory and Clinical Medicine
ISSN
0022-2143JCR Link
Citation
Journal of Laboratory and Clinical Medicine vol. 144, no. 3, pp. 156 - 162
Indexed
SCOPUS WOS scopus
Document Type
Article
Abstract
Arteriovenous polytetrafluoroethylene (PTFE) grafts used for hemodialysis often fail as the result of myointimal hyperplasia with vascular smooth-muscle-cell (SMC) proliferation. The stenotic lesions occur primarily at the graft-vein anastomosis and less frequently at the graft-artery anastomosis. To explore the potentials of pharmacologic agents in preventing hemodialysis-graft stenosis, we first examined the susceptibility of venous and aortic SMCs to 3 antiproliferative drugs. Human aortic and saphenous-vein SMCs were cultured in a medium containing insulin, epidermal growth factor, fibroblast growth factor, and fetal bovine serum. Various concentrations of dipyridamole (0-100 μg/mL), paclitaxel (0-100 μg/mL), and tranilast (0-300 μg/mL) were added. After 72 hours, we subjected the cells to a mitochondrial enzymatic (methylthiazoletetrazolium; MTT) assay and a bromodeoxyuridine (BrdU)-incorporation assay as a means of assessing their proliferation. Dipyridamole, paclitaxel, and tranilast each inhibited the proliferation of aortic and venous SMCs in a dose-dependent manner (P < .0001). Approximately 90% inhibition was achieved at dipyridamole concentrations of 75 μg/mL and greater in both MTT and BrdU assays; paclitaxel and tranilast were less effective. The venous SMCs were substantially more susceptible to inhibition by all 3 drugs than were the aortic SMCs in the MTT assay. The concentrations required to produce 50% inhibition (IC 50) in the venous cells were 5.8 μg/mL (11.5 μmol/L), 9.1 μg/mL (10.7 μmol/L), and 37.4 μg/mL (114.3 μmol/L), respectively, for dipyridamole, paclitaxel, and tranilast. These concentrations were approximately 4.2, 5.3, and 3.0 times lower, respectively, than the corresponding IC 50 values for the aortic cells. The differences in IC 50 between the aortic and venous cells for the 3 drugs were less pronounced in the BrdU assay. The results of this study suggest that strategies for the prevention of stenosis should take into account the fact that lesions at venous anastomoses of arteriovenous grafts may respond differently to drugs than do those at arterial anastomoses.
DOI
10.1016/j.lab.2004.06.002
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE